Australian Second Skin Technology Company to List on UK Exchange

Gold Coast, Australia (PressExposure) March 01, 2013 -- Australian skin simulation technology company Microskin has announced its intention to list on the UK based GXG exchange.

The company produces a revolutionary simulated second skin individually formulated to color correct a range of conditions such as dermatitis, eczema, psoriasis and vitiligo.

Microskin has already achieved considerable success both in Australia and overseas including establishing franchises in the US, Europe, the Middle East and Indonesia.

Executive chairman, Barry Amor, says Microskin is now in a position to be able to list on an exchange, and the GXG offered the best initial option for international expansion.

"Microskin's listing will provide the necessary capital to support our international expansion plans, particularly to establish further franchises," Mr Amor says.

"The GXG is a European regulated market and provides a more competitive environment for raising capital and trading of shares, especially on a global scale.

"It will also give us access to a much larger consumer base, so all these factors make it an attractive option to list."

Microskin has appointed corporate advisors Stepping Stone Equity to complete the process and to finalise a prospectus to comply with the exchange's official list, paving the way for a dual listing on the Frankfurt Stock Exchange.

Mr Amor says Microskin's successful and profitable track record over the past eight years has enabled it to build a sizeable franchise network, however liquidity in the company is required for further expansion. "While we have achieved considerable domestic and international success to date, we are now focussing our energies on new markets which will give us a far greater opportunity to further our expansion plans," Mr Amor says.

"We are already well underway with negotiations for a number of new franchise agreements and product development to supplement our flagship offering.

"Our listing strategy will provide us with both the capital and opportunities to continue our research and development and help to secure our place as a dominant player in our industry worldwide."

The listing proposal has already been presented to Microskin shareholders for final approval and is expected to be completed in the coming days. For more information or to register interest in Microskin's listing visit

For all media enquiries contact Bruce Nelson on +61 (0) 423 403 449.

About Microskin


Bruce Nelson

Press Release Source:

Press Release Submitted On: February 28, 2013 at 6:07 pm
This article has been viewed 21485 time(s).